全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

A Case of Primary T-Cell Central Nervous System Lymphoma: MR Imaging and MR Spectroscopy Assessment

DOI: 10.1155/2013/916348

Full-Text   Cite this paper   Add to My Lib

Abstract:

Primary central nervous system lymphomas (PCNSLs) are mainly B-cells lymphomas. A risk factor for the development of PCNSL is immunodeficiency, which includes congenital disorders, iatrogenic immunosuppression, and HIV. The clinical course is rapidly fatal; these patients usually present signs of increased intracranial pressure, nausea, papilledema, vomiting, and neurological and neuropsychiatric symptoms. PCNSL may have a characteristic appearance on CT and MR imaging. DWI sequences and MR spectroscopy may help to differentiate CNS lymphomas from other brain lesions. In this paper, we report a case of a 23-year-old man with T-primary central nervous system lymphoma presenting with a mass in the right frontotemporal lobe. We describe clinical, CT, and MRI findings. Diagnosis was confirmed by stereotactic biopsy of the lesion. 1. Introduction PCNSL causes approximately 3%-4% of all primary brain tumors. PCNSL is defined as lymphoma in the central nervous System (CNS) without primary tumor elsewhere. PCNSL is mainly diffuse large B-cell lymphoma; less common PCNSL histological types are Burkitt’s lymphoma and T-cell lymphoma. Our case is about a 23-year old man with T-cell central nervous system lymphoma (T-PCNSL). 2. Clinical History A 23-year-old man was referred to our emergency room because of nausea, vomiting with associated acute confusional state. Neurological examination revealed slow response, postural instability without rigidity or tremor in any of the four extremities, and normal sensation. No remarkable abnormality was observed at the physical examination. Laboratory tests were within normal limits, in exception for LDH 61,1?mU/mL (5–36?mU/mL normal range). Past medical history was negative for considerable pathologies. HIV status of the patient was positive. Computed tomography (CT) of the brain revealed a ?cm mild hyperdense mass in the right frontotemporal region with associated perilesional oedema. Mild mass effect on the homolateral ventricle was observed with 1?cm midline shift. CT also revealed the presence of another similar lesion measuring 3,5?cm localized in the right cerebellar lobe (Figure 1). Figure 1: Axial CT acquisition (a)-(b) with sagittal (c) and coronal (d) multiplanar reformatted images showing a mild hyperdense complex lobulated mass in the right frontotemporal region associated with oedema and a similar smaller lesion in the right cerebellar lobe. In the next, CT scan was integrated with brain MRI and single-voxel (1)H MR spectroscopy. Diffusion weighted imaging (DWI) showed hyperintense lesions at the right

References

[1]  Y. Shibamoto, H. Ogino, G. Suzuki et al., “Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985–2004,” Neuro-Oncology, vol. 10, no. 4, pp. 560–568, 2008.
[2]  D. Zhang, L. B. Hu, T. D. Henning et al., “MRI findings of primary CNS lymphoma in 26 immunocompetent patients,” Korean Journal of Radiology, vol. 11, no. 3, pp. 269–277, 2010.
[3]  L. M. DeAngelis, “Primary central nervous system lymphoma,” Recent Results in Cancer Research, vol. 135, pp. 155–169, 1994.
[4]  A. J. M. Ferreri, M. Reni, and E. Villa, “Primary central nervous system lymphoma in immunocompetent patients,” Cancer Treatment Reviews, vol. 21, no. 5, pp. 415–446, 1995.
[5]  J. L. Villano, M. Koshy, H. Shaikh, T. A. Dolecek, and B. J. McCarthy, “Age, gender, and racial differences in incidence and survival in primary CNS lymphoma,” British Journal of Cancer, vol. 105, no. 9, pp. 1414–1418, 2011.
[6]  M. S. Mathews, D. A. Bota, R. C. Kim, A. N. Hasso, and M. E. Linskey, “Primary leptomeningeal plasmablastic lymphoma,” Journal of Neuro-Oncology, vol. 104, no. 3, pp. 835–838, 2011.
[7]  I. S. Haldorsen, A. Espeland, and E. M. Larsson, “Central nervous system lymphoma: characteristic findings on traditional and advanced imaging,” American Journal of Neuroradiology, vol. 32, no. 6, pp. 984–992, 2011.
[8]  T. Lim, S. J. Kim, K. Kim, et al., “Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes,” Annals of Hematology, vol. 90, no. 12, pp. 1391–1398, 2011.
[9]  L. E. Abrey, L. M. DeAngelis, and J. Yahalom, “Long-term survival in primary CNS lymphoma,” Journal of Clinical Oncology, vol. 16, no. 3, pp. 859–863, 1998.
[10]  A. Doskaliyev, F. Yamasaki, M. Ohtaki et al., “Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T,” European Journal of Radiology, vol. 81, no. 2, pp. 339–344, 2012.
[11]  R. F. Barajas Jr., J. L. Rubenstein, J. S. Chang, J. Hwang, and S. Cha, “Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma,” American Journal of Neuroradiology, vol. 31, no. 1, pp. 60–66, 2010.
[12]  N. Kawai, M. Okada, R. Haba, Y. Yamamoto, and T. Tamiya, “Insufficiency of positron emission tomography and magnetic resonance spectroscopy in the diagnosis of intravascular lymphoma of the central nervous system,” Case Reports in Oncology, vol. 5, no. 2, pp. 339–346, 2012.
[13]  M. F. Chernov, T. Kawamata, K. Amano et al., “Possible role of single-voxel 1H-MRS in differential diagnosis of suprasellar tumors,” Journal of Neuro-Oncology, vol. 91, no. 2, pp. 191–198, 2009.
[14]  W. M?ller-Hartmann, S. Herminghaus, T. Krings, et al., “Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions,” Neuroradiology, vol. 44, no. 5, pp. 371–381, 2002.
[15]  Y. Z. Tang, T. C. Booth, P. Bhogal, A. Malhotra, and T. Wilhelm, “Imaging of primary central nervous system lymphoma,” Clinical Radiology, vol. 66, no. 8, pp. 768–777, 2011.
[16]  M. Reni, A. J. M. Ferreri, N. Guha-Thakurta et al., “Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate,” International Journal of Radiation Oncology, Biology, Physics, vol. 51, no. 2, pp. 419–425, 2001.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413